6. M.F. Al-Omran, S.A. Al-Suwayeh, A.M. El-Helw, S.I. Saleh. T<strong>as</strong>te m<strong>as</strong>king <strong>of</strong>dicl<strong>of</strong>enac sodium using microencapsulation. J Microencapsul. 19 (2002) 45-52.7. P.P. Shah, R.C. M<strong>as</strong>hru, Y.M. Rane, A. Thakkar. Design and optimization <strong>of</strong>mefloquine hydrochloride microparticles <strong>for</strong> bitter t<strong>as</strong>te m<strong>as</strong>king. AAPSPharmSciTech. 9 (2008) 377-89.8. S.S. Behzadi, T. Toegel, H. Viernstein. Innovations in coating technology. Recent PatDrug Deliv Formul. 2 (2008) 209-30.9. T. Ham<strong>as</strong>hita, M. Matsuzaki, T. Ono, M. Ono, Y. Tsunenari, T. Aketo, S. Watano.Granulation <strong>of</strong> core particles suitable <strong>for</strong> film coating by agitation fluidized bed II. Aproposal <strong>of</strong> a rapid dissolution test <strong>for</strong> evaluation <strong>of</strong> bitter t<strong>as</strong>te <strong>of</strong> ibupr<strong>of</strong>en. ChemPharm Bull, (Tokyo). 56 (2008) 883-7.10. J.P. Benoit, H. Rolland, C. Thies, V. Vande Velde. Method <strong>of</strong> coating particles andcoated spherical particles. US Patent: 6,087,003 (2000)11. H. Mazen, P. York. Particle <strong>for</strong>mation methods and <strong>the</strong>ir products. US Patent:7,115,280 (2006)12. A. Forster, J. Hempenstall, T. Rades. Characterization <strong>of</strong> gl<strong>as</strong>s solutions <strong>of</strong> poorlywater-soluble drugs produced by <strong>melt</strong>s <strong>extrusion</strong> with hydrophilic amorphouspolymers. J Pharm Pharmacol, 53 (2001) 303–315.13. M. Kinoshita, K. Baba, A. Nagay<strong>as</strong>u, K. Yamabe, T. Shimooka, Y. Takeichi et al.Iimprovement <strong>of</strong> solubility and oral bioavailability <strong>of</strong> a poorly water-soluble drug,TAS-301, by its <strong>melt</strong>-adsorption on a porous calcium silicate. J Pharm Sci, 91 (2002)362–370.14. J. Breitenbach, M. Magerlein. Melt extruded molecular dispersions. In I. Ghebre-Sell<strong>as</strong>sie & C. Martin (Eds.), Pharmaceutical Extrusion Technology, New York:Marcel Dekker Inc. 2003.15. I. Ozgüney, D. Shuwisitkul, R. Bodmeier. <strong>Development</strong> and characterization <strong>of</strong>extended rele<strong>as</strong>e Kollidon SR mini-matrices prepared by <strong>hot</strong>-<strong>melt</strong> <strong>extrusion</strong>. Eur. JPharm. Biopharm. 73 (2009) 140-5.16. E. Verhoeven, C. Vervaet, J.P. Remon. Xanthan gum to tailor drug rele<strong>as</strong>e <strong>of</strong>sustained-rele<strong>as</strong>e ethylcellulose mini-matrices prepared via <strong>hot</strong>-<strong>melt</strong> <strong>extrusion</strong>: invitro and in vivo evaluation. Eur J Pharm Biopharm. 63 (2006) 320-3.17. C. De Brabander, C. Vervaet, J.P. Remon. <strong>Development</strong> and evaluation <strong>of</strong> sustainedrele<strong>as</strong>e mini-matrices prepared via <strong>hot</strong> <strong>melt</strong> <strong>extrusion</strong>. J Cont Rel. 89 (2002) 235-47.61 | P a g e
18. Verhoeven, T.R.M. De Beer, E. Schacht, G. Van den Mooter, J.P. Remon, C. Vervaet.Influence <strong>of</strong> polyethylene glycol/polyethylene oxide on <strong>the</strong> rele<strong>as</strong>e characteristics <strong>of</strong>sustained-rele<strong>as</strong>e ethylcellulose mini-matrices produced by <strong>hot</strong>-<strong>melt</strong> <strong>extrusion</strong>: invitro and in vivo evaluations. Eur J Pharm Biopharm. 72 (2009) 463-470.19. Innovative <strong>for</strong>mulations from Melt Extrusionhttp://eudragit.evonik.com/product/eudragit/en/downloads/eudragitbrochures/pages/default.<strong>as</strong>px.20. A. Fini, G. Fazio, G. Feroci. Solubility and solubilisation properties <strong>of</strong> non-steroidalanti-inflammatory drugs. Int J Pharm.126 (1995) 95–102.21. N.A. Pepp<strong>as</strong>, P.A. Buri. Surface, interfacial and molecular <strong>as</strong>pects <strong>of</strong> polymerbioadhesion on s<strong>of</strong>t tissues J Control Rel. 2 (1985) 257–75.22. J.T. Fell, J.M. Newton. Determination <strong>of</strong> tablet strength by diametral – compressiontest. J Pharm Sci, 59 (1970) 688 – 91.23. C.K. Tye, C.C. Sun, G.E. Amidon. Evaluation <strong>of</strong> <strong>the</strong> effects <strong>of</strong> tableting speed on <strong>the</strong>relationships between compaction pressure, tablet tensile strength, and tablet solidfraction. J Pharm Sci. 94 (2005) 465-67.24. G. Abdelbary, C. Eouani, P. Prinderre, J. Joachim, J.P. Reynier, P. Piccerelle.Determination <strong>of</strong> <strong>the</strong> in vitro disintegration pr<strong>of</strong>ile <strong>of</strong> rapidly disintegrating tabletsand correlation with oral disintegration. Int J Pharm. 292 (2005) 29–41.25. S. Khan, P. Kataria, P. Nakhat, Y.P. Pramod. T<strong>as</strong>te M<strong>as</strong>king <strong>of</strong> OndansetronHydrochloride by Polymer Carrier System and Formulation <strong>of</strong> Rapid-DisintegratingTablets. AAPS PharmSciTech. 8 (2007) E1 – E7.26. H. Goel, N. Vora, V. Rana. A Novel Approach to Optimize and Formulate F<strong>as</strong>tDisintegrating Tablets <strong>for</strong> Nausea and Vomiting. AAPS PharmSciTech. 9 (2008) 774– 781.27. S. Qi, A. Gryczke, P. Belton, D.Q. Craig. Characterisation <strong>of</strong> solid dispersions <strong>of</strong>paracetamol and EUDRAGIT E prepared by <strong>hot</strong>-<strong>melt</strong> <strong>extrusion</strong> using <strong>the</strong>rmal,micro<strong>the</strong>rmal and spectroscopic analysis. Int J Pharm. 354 (2008) 158-67.28. C. De Brabander, G. Van Den Mooter, C. Vervaet, J.P. Remon. Characterization <strong>of</strong>ibupr<strong>of</strong>en <strong>as</strong> a nontraditional pl<strong>as</strong>ticizer <strong>of</strong> ethyl cellulose. J Pharm Sci. 91 (2002)1678-85.29. M. Wesseling, F. Kuppler, R. Bodmeier. Tackiness <strong>of</strong> acrylic and cellulosic polymerfilms used in <strong>the</strong> coating <strong>of</strong> solid dosage <strong>for</strong>ms. Eur J Pharm Biopharm. 47 (1999) 73-8.62 | P a g e
- Page 3 and 4:
DECLARATION“I certify that this w
- Page 6 and 7:
taste masking effect of the process
- Page 8 and 9:
CHAPTER 2: DISSOLUTION ENHANCEMENT
- Page 10 and 11:
3.2 Powder and ODT characterization
- Page 12 and 13:
3.7 In vitro drug release profiles
- Page 15:
3.1 Solubility parameters and extru
- Page 18 and 19:
polymers.7.2 DSC findings of all AP
- Page 20 and 21:
2.4b Diffractograms of FMT formulat
- Page 22 and 23:
4.3 Schematic representation of the
- Page 24 and 25:
55 exrudates (b) DPD/L100-55 PM (c)
- Page 26 and 27:
8.5d A plot of the logarithm of HCS
- Page 28 and 29:
L100Eudragit L100L100-55 Eudragit L
- Page 30 and 31:
Maniruzzaman M, Rai D, Boateng JS.
- Page 32 and 33:
Maniruzzaman M, Boateng JS, Bonnefi
- Page 34 and 35:
CHAPTER 1: INTRODUCTION1.0 Backgrou
- Page 36 and 37:
Table 1.1: HME and other convention
- Page 38 and 39:
homogenize but also compress the ex
- Page 40 and 41:
properties of polymers and excipien
- Page 42 and 43:
particles‘ wettability [46] . A v
- Page 44 and 45: Table 1.2: Different hot-melt extru
- Page 46 and 47: 1.8 Aims and objectivesThe purpose
- Page 48 and 49: 29. Zheng X, Yang R, Tang X and Zhe
- Page 50 and 51: 56. International Conference on Har
- Page 52 and 53: CHAPTER 2: DISSOLUTION ENHANCEMENT
- Page 54 and 55: Fdid ,Vi F2pip , p( Ehi/ ViVi )i =
- Page 56 and 57: used. Each sample was scanned from
- Page 58 and 59: Furthermore, by means of thermodyna
- Page 60 and 61: 3.2 Particle size morphology and pa
- Page 62 and 63: Fig. 2.4a: Diffractograms of INM fo
- Page 64 and 65: However, the DSC thermograms of the
- Page 66 and 67: Fig. 2.5b: DSC thermograms of INM a
- Page 68 and 69: Fig. 2.5e: DSC thermograms of FMT a
- Page 70 and 71: Nevertheless, more than 80% FMT was
- Page 72 and 73: 6. Caron V, Tajber L, Corrigan OI,
- Page 74 and 75: CHAPTER 3: DEVELOPMENT AND EVALUATI
- Page 76 and 77: 2.2 Hot-Melt extrusionHot-melt extr
- Page 78 and 79: Committee of the University of Gree
- Page 80 and 81: The PM of formulation II (40% IBU)
- Page 82 and 83: Fig. 3.3: DSC thermograms of pure I
- Page 84 and 85: As a general rule, the powder compr
- Page 86 and 87: Fig. 3.4: Schematic diagram of ODT
- Page 88 and 89: Fig. 3.5: Schematic diagram of ODTs
- Page 90 and 91: Fig. 3.7: Schematic diagram of ODTs
- Page 92 and 93: F2 0 0.5 0 1 0 1F6 0 0.5 0 1 0 2F7
- Page 96 and 97: 30. L. Saerens, L. Dierickx, B. Len
- Page 98 and 99: leading to significant variations w
- Page 100 and 101: 2.6. In vitro drug release studiesI
- Page 102 and 103: v2d 2p(4.1)Table 4.1: Calculated so
- Page 104 and 105: The observed melting peaks are shif
- Page 106 and 107: Fig. 4.2a: Powder XRPD patterns of
- Page 108 and 109: Interestingly, no difference was ob
- Page 110 and 111: 7 Astree sensors Taste masking effi
- Page 112 and 113: The in vitro e-tongue evaluation wa
- Page 114 and 115: 3. K. Woertz, C. Tissen, P. Kleineb
- Page 116 and 117: 25. B.C. Hancock, P. York, R.C. Row
- Page 118 and 119: CHAPTER 5: AN IN VIVO AND IN VITRO
- Page 120 and 121: (dispersion forces and polarization
- Page 122 and 123: Table 5.1: Sample preparation for t
- Page 124 and 125: Table 5.2: Solubility parameters ca
- Page 126 and 127: Physical mixtures (PM) and extruded
- Page 128 and 129: Fig. 5.2c: Thermograms of CTZ and V
- Page 130 and 131: masking effect for active concentra
- Page 132 and 133: Fig. 5.5b: Distance and discriminat
- Page 134 and 135: Table 5.4: Mean standard deviation
- Page 136 and 137: Fig. 5.6b: Release profiles of VRP
- Page 138 and 139: 17. Woertz K,Tissen C, Kleinebudde
- Page 140 and 141: scale or lower. XPS is more accurat
- Page 142 and 143: patterns were identified after ener
- Page 144 and 145:
3.3 Differential scanning calorimet
- Page 146 and 147:
Fig. 6.3a: Diffractograms of PRP fo
- Page 148 and 149:
good agreement with the anticipated
- Page 150 and 151:
Since L100 contained higher proport
- Page 152 and 153:
at ~533.01 eV is the combination of
- Page 154 and 155:
Finally, the XPS analysis confirmed
- Page 156 and 157:
Fig. 6.6b: 1 H NMR spectra of all P
- Page 158 and 159:
6) Bonferoni, M.C.; Rossi, S.; Ferr
- Page 160 and 161:
26) Vandencasteele, N.; Reniers, F.
- Page 162 and 163:
Gibbs free energy change before and
- Page 164 and 165:
2.5 Hot-melt extrusion (HME) proces
- Page 166 and 167:
2.11 X-ray photoelectron spectrosco
- Page 168 and 169:
Table 7.2: DSC findings of all APIs
- Page 170 and 171:
3.4 In vivo and in vitro taste mask
- Page 172 and 173:
Fig. 7.3c: Normalised DI (%) of all
- Page 174 and 175:
Table 7.4: Binding energy calculati
- Page 176 and 177:
PRP/ polymers extruded in compariso
- Page 178 and 179:
atom as NH + 4 . This observed N 1s
- Page 180 and 181:
8.0 ConclusionsThe presence of inte
- Page 182 and 183:
20. Davies MC, Wilding IR, Short RD
- Page 184 and 185:
CHAPTER 8: SUSTAINED RELEASE HYDROC
- Page 186 and 187:
2.3 Preparation of formulation blen
- Page 188 and 189:
medium pH was maintained as 1.2 by
- Page 190 and 191:
Fig. 8.1: SEM images of [(a), (b)]
- Page 192 and 193:
Fig. 8.2b: DSC transitions of HCS/E
- Page 194 and 195:
in the range of 10-12 kP. However,
- Page 196 and 197:
ate and time on the basis of Eq. (8
- Page 198 and 199:
Fig. 8.5c: A plot of the cubic root
- Page 200 and 201:
when n > 0.89. From the results of
- Page 202 and 203:
14. Lam PL, Lee KKH,Wong RSM, Cheng
- Page 204 and 205:
Furthermore, HME has successfully b
- Page 206 and 207:
Supp. Fig. 2: XPS O 1s peaks for PR
- Page 208 and 209:
Supp. Fig. 4: O 1s BE peaks for L10
- Page 210 and 211:
8.2 s 6.2 s 3.8 s 1.8 s 200 msS
- Page 212 and 213:
12.2 s 9.0 s 6.2 s 3.8 s 1.8 s
- Page 214 and 215:
Supplementary table 1: Solubility p
- Page 216 and 217:
N = 55000/ 219.2 = 250.912Density:
- Page 218 and 219:
(4) Eudragit L100, N = (125000/202